Brain metastases from lung adenocarcinoma (BM-LUAD) frequently cause patient mortality.
To identify genomic alterations that promote brain metastases, we performed whole-exome …

Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that
potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance …

Background Identification of variable epidermal growth factor receptor (EGFR) gene
mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate …

The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …

Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …

Lung cancer (LC), the leading cause of cancer-related deaths worldwide, is a complex and
highly heterogeneous disease. Additional to its biological complexity, LC patients are often …

Gallbladder cancer (GBC) is rare, but is the most malignant type of biliary tract tumor.
Unfortunately, only a small population of cancer patients is acceptable for the surgical …

Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling
has enriched our understanding of cancer initiation and progression and has become …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …

Brain metastases (BM) are the most commonly diagnosed type of central nervous system
tumor in the United States. Estimates of the frequency of BM vary significantly, as there is no …